PARAPLATIN® and VEPESID® with TECENTRIQ® - for Small Cell Lung Cancer
PARAPLATIN® (Carboplatin) and VEPESID® (Etoposide) along with TECENTRIQ® (Atezolizumab) for Extensive Stage Small Cell Lung Cancer
Administer TECENTRIQ® prior to chemotherapy when administered on the same day. If the first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Monitor patients for Infusion-Related Reactions and Immune-Mediated adverse events. TECENTRIQ® continued until disease progression or unacceptable toxicities.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
PARAPLATIN® (Carboplatin) IV AUC 5  D1 q21 NSS 250 cc 60 minutes
VEPESID® (Etoposide) IV 100 mg/m2 D1, D2, D3 q21 NSS 500 cc 90 minutes
TECENTRIQ® (Atezolizumab) IV 1200 mg D1 q21 NSS 250 cc 60 minutes